View ValuationSinil Pharmaceutical 将来の成長Future 基準チェック /06現在、 Sinil Pharmaceuticalの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長20.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Mar 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.3% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (9.3% net profit margin). Market cap is less than US$100m (₩67.6b market cap, or US$45.2m).お知らせ • Mar 12Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 28, boksanggol-gil, angseong-myeon, chungcheongbuk-do, chungju South KoreaReported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₩20.6b (flat on 3Q 2024). Net income: ₩2.61b (down 5.9% from 3Q 2024). Profit margin: 13% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Mar 08Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 24, 2025Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 24, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 28, boksanggol-gil, angseong-myeon, chungcheongbuk-do, chungju South KoreaReported Earnings • Nov 20Third quarter 2024 earnings released: EPS: ₩240 (vs ₩300 in 3Q 2023)Third quarter 2024 results: EPS: ₩240 (down from ₩300 in 3Q 2023). Revenue: ₩20.6b (down 19% from 3Q 2023). Net income: ₩2.77b (down 20% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.分析記事 • Aug 12Little Excitement Around Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) EarningsSinil Pharmaceutical Co., Ltd.'s ( KOSDAQ:012790 ) price-to-earnings (or "P/E") ratio of 6.8x might make it look like a...Upcoming Dividend • Dec 20Upcoming dividend of ₩96.15 per share at 1.3% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).New Risk • Nov 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩82.1b market cap, or US$63.5m).Reported Earnings • Nov 20Third quarter 2023 earnings released: EPS: ₩300 (vs ₩213 in 3Q 2022)Third quarter 2023 results: EPS: ₩300 (up from ₩213 in 3Q 2022). Revenue: ₩25.4b (up 25% from 3Q 2022). Net income: ₩3.47b (up 41% from 3Q 2022). Profit margin: 14% (up from 12% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.Reported Earnings • May 19First quarter 2023 earnings released: EPS: ₩329 (vs ₩217 in 1Q 2022)First quarter 2023 results: EPS: ₩329 (up from ₩217 in 1Q 2022). Revenue: ₩21.8b (up 22% from 1Q 2022). Net income: ₩3.80b (up 51% from 1Q 2022). Profit margin: 17% (up from 14% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Dec 21Upcoming dividend of ₩97.09 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (1.0%).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Buying Opportunity • Oct 11Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be ₩9,912, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 5.7%.Buying Opportunity • Sep 16Now 20% undervaluedOver the last 90 days, the stock is up 2.1%. The fair value is estimated to be ₩10,911, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 5.7%.Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩10,150, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 67% over the past three years.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩8,260, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Inaugural dividend of ₩97.09 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Sinil Pharmaceutical since going public. The average dividend yield among industry peers is 0.8%.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩11,600, the stock trades at a trailing P/E ratio of 22.8x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 59% over the past three years.Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩19,150, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 168% over the past three years.Valuation Update With 7 Day Price Move • Apr 12Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩15,850, the stock trades at a trailing P/E ratio of 22.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 50% over the past three years.分析記事 • Mar 11Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials Driving The Negative Sentiment?With its stock down 41% over the past three months, it is easy to disregard Sinil Pharmaceutical (KOSDAQ:012790). It is...分析記事 • Feb 13Is Sinil Pharmaceutical's (KOSDAQ:012790) 122% Share Price Increase Well Justified?It hasn't been the best quarter for Sinil Pharmaceutical Co., Ltd. ( KOSDAQ:012790 ) shareholders, since the share...分析記事 • Jan 17Could The Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790) Ownership Structure Tell Us Something Useful?The big shareholder groups in Sinil Pharmaceutical Co., Ltd. ( KOSDAQ:012790 ) have power over the company. Insiders...Is New 90 Day High Low • Jan 15New 90-day low: ₩19,000The company is down 19% from its price of ₩23,592 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period.Valuation Update With 7 Day Price Move • Jan 14Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩20,150, the stock is trading at a trailing P/E ratio of 26.1x, down from the previous P/E ratio of 30.9x. This compares to an average P/E of 29x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 141%.分析記事 • Dec 22Sinil Pharmaceutical's (KOSDAQ:012790) Earnings Are Growing But Is There More To The Story?As a general rule, we think profitable companies are less risky than companies that lose money. Having said that...Valuation Update With 7 Day Price Move • Dec 02Market bids up stock over the past weekAfter last week's 15% share price gain to ₩25,800, the stock is trading at a trailing P/E ratio of 32.4x, up from the previous P/E ratio of 28.1x. This compares to an average P/E of 30x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 199%.分析記事 • Nov 26Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?It is hard to get excited after looking at Sinil Pharmaceutical's (KOSDAQ:012790) recent performance, when its stock...Is New 90 Day High Low • Nov 11New 90-day low: ₩20,300The company is down 23% from its price of ₩26,300 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 18New 90-day low: ₩24,300The company is down 8.0% from its price of ₩26,500 on 20 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Sinil Pharmaceutical は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A012790 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202580,5647,5317,67611,589N/A9/30/202580,97211,3117,79413,267N/A6/30/202580,97811,4757,43415,261N/A3/31/202585,92112,65410,67119,082N/A12/31/202489,44014,30112,23222,689N/A9/30/202491,69915,06622,35226,372N/A6/30/202496,51615,76316,00325,797N/A3/31/202490,06413,5057,81820,267N/A12/31/202389,13513,6411,49415,154N/A9/30/202386,21012,624-10,00711,359N/A6/30/202381,16311,613-5,58310,633N/A3/31/202383,91413,444-2,34311,173N/A12/31/202280,00712,1573,30913,688N/A9/30/202275,97111,0675,76613,015N/A6/30/202272,08210,3438,69014,181N/A3/31/202266,4358,2299,44712,494N/A12/31/202161,7546,6797,53411,163N/A9/30/202160,1775,2016,73311,856N/A6/30/202159,4355,40707,464N/A3/31/202159,3236,4941,40410,884N/A12/31/202061,4387,5442,15911,062N/A9/30/202063,7368,3591,75211,289N/A6/30/202063,6138,0726,88314,826N/A3/31/202063,5478,0176,10314,604N/A12/31/201960,6487,2572,56912,306N/A9/30/201957,3977,115N/A11,872N/A6/30/201954,2525,497N/A10,138N/A3/31/201953,2414,767N/A6,987N/A12/31/201853,2775,714N/A9,194N/A9/30/201852,4426,385N/A2,244N/A6/30/201852,8677,888N/A5,287N/A3/31/201851,3698,293N/A10,089N/A12/31/201750,9428,198N/A8,674N/A9/30/201750,5457,731N/A20,427N/A6/30/201749,3878,376N/A15,158N/A3/31/201749,1588,840N/A10,757N/A12/31/201650,2129,360N/A12,094N/A9/30/201649,1349,432N/A5,350N/A6/30/201648,1519,352N/A8,080N/A3/31/201646,9649,117N/A7,855N/A12/31/201544,7038,764N/A9,564N/A9/30/201545,2409,405N/A12,112N/A6/30/201546,8059,905N/A11,273N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A012790の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A012790の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A012790の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A012790の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A012790の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A012790の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 05:34終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sinil Pharmaceutical Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Mar 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.3% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (9.3% net profit margin). Market cap is less than US$100m (₩67.6b market cap, or US$45.2m).
お知らせ • Mar 12Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 28, boksanggol-gil, angseong-myeon, chungcheongbuk-do, chungju South Korea
Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₩20.6b (flat on 3Q 2024). Net income: ₩2.61b (down 5.9% from 3Q 2024). Profit margin: 13% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Mar 08Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 24, 2025Sinil Pharmaceutical Co., Ltd., Annual General Meeting, Mar 24, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 28, boksanggol-gil, angseong-myeon, chungcheongbuk-do, chungju South Korea
Reported Earnings • Nov 20Third quarter 2024 earnings released: EPS: ₩240 (vs ₩300 in 3Q 2023)Third quarter 2024 results: EPS: ₩240 (down from ₩300 in 3Q 2023). Revenue: ₩20.6b (down 19% from 3Q 2023). Net income: ₩2.77b (down 20% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
分析記事 • Aug 12Little Excitement Around Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) EarningsSinil Pharmaceutical Co., Ltd.'s ( KOSDAQ:012790 ) price-to-earnings (or "P/E") ratio of 6.8x might make it look like a...
Upcoming Dividend • Dec 20Upcoming dividend of ₩96.15 per share at 1.3% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
New Risk • Nov 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩82.1b market cap, or US$63.5m).
Reported Earnings • Nov 20Third quarter 2023 earnings released: EPS: ₩300 (vs ₩213 in 3Q 2022)Third quarter 2023 results: EPS: ₩300 (up from ₩213 in 3Q 2022). Revenue: ₩25.4b (up 25% from 3Q 2022). Net income: ₩3.47b (up 41% from 3Q 2022). Profit margin: 14% (up from 12% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
Reported Earnings • May 19First quarter 2023 earnings released: EPS: ₩329 (vs ₩217 in 1Q 2022)First quarter 2023 results: EPS: ₩329 (up from ₩217 in 1Q 2022). Revenue: ₩21.8b (up 22% from 1Q 2022). Net income: ₩3.80b (up 51% from 1Q 2022). Profit margin: 17% (up from 14% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Dec 21Upcoming dividend of ₩97.09 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (1.0%).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Buying Opportunity • Oct 11Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be ₩9,912, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 5.7%.
Buying Opportunity • Sep 16Now 20% undervaluedOver the last 90 days, the stock is up 2.1%. The fair value is estimated to be ₩10,911, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 5.7%.
Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩10,150, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 67% over the past three years.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩8,260, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Inaugural dividend of ₩97.09 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Sinil Pharmaceutical since going public. The average dividend yield among industry peers is 0.8%.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩11,600, the stock trades at a trailing P/E ratio of 22.8x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 59% over the past three years.
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩19,150, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 168% over the past three years.
Valuation Update With 7 Day Price Move • Apr 12Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩15,850, the stock trades at a trailing P/E ratio of 22.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 50% over the past three years.
分析記事 • Mar 11Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials Driving The Negative Sentiment?With its stock down 41% over the past three months, it is easy to disregard Sinil Pharmaceutical (KOSDAQ:012790). It is...
分析記事 • Feb 13Is Sinil Pharmaceutical's (KOSDAQ:012790) 122% Share Price Increase Well Justified?It hasn't been the best quarter for Sinil Pharmaceutical Co., Ltd. ( KOSDAQ:012790 ) shareholders, since the share...
分析記事 • Jan 17Could The Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790) Ownership Structure Tell Us Something Useful?The big shareholder groups in Sinil Pharmaceutical Co., Ltd. ( KOSDAQ:012790 ) have power over the company. Insiders...
Is New 90 Day High Low • Jan 15New 90-day low: ₩19,000The company is down 19% from its price of ₩23,592 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period.
Valuation Update With 7 Day Price Move • Jan 14Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩20,150, the stock is trading at a trailing P/E ratio of 26.1x, down from the previous P/E ratio of 30.9x. This compares to an average P/E of 29x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 141%.
分析記事 • Dec 22Sinil Pharmaceutical's (KOSDAQ:012790) Earnings Are Growing But Is There More To The Story?As a general rule, we think profitable companies are less risky than companies that lose money. Having said that...
Valuation Update With 7 Day Price Move • Dec 02Market bids up stock over the past weekAfter last week's 15% share price gain to ₩25,800, the stock is trading at a trailing P/E ratio of 32.4x, up from the previous P/E ratio of 28.1x. This compares to an average P/E of 30x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 199%.
分析記事 • Nov 26Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?It is hard to get excited after looking at Sinil Pharmaceutical's (KOSDAQ:012790) recent performance, when its stock...
Is New 90 Day High Low • Nov 11New 90-day low: ₩20,300The company is down 23% from its price of ₩26,300 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 18New 90-day low: ₩24,300The company is down 8.0% from its price of ₩26,500 on 20 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period.